-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

Benzinga·09/30/2026 18:04:59
Listen to the news
JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.